Grant: Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops
Unity Health Toronto
$499,302.00
Ab-C Risk: Action to Beat Coronavirus Sub-study on Population Immunity in High-Risk Groups in Canada
FY 2021-22
Summary
We have been studying the impact of SARS-CoV-2 infection and vaccination on immunity among a representative sample of about 20,000 Canadian adults, in the Action to Beat Coronavirus in Canada (Ab-C) study, since early in the pandemic. Ab-C Risk will recruit an additional 1,000 Canadians belonging to higher risk demographic and ethnic groups. The Ab-C cohort was recruited in collaboration with the Angus Reid Institute, which will continue to lead in surveying participants periodically about COVID-related experiences, including infection, clinical signs and symptoms, exposures, PCR testing for the virus (including variants of concern), and vaccination. Ab-C relies on participants to self-collect finger prick blood samples on special paper, and send them to Unity Health for analysis for SARS-CoV-2 antibodies. Three rounds of surveys and blood samples have been completed. A fourth and fifth round, planned into 2022, will include the new Ab-C Risk cohort.
The main Ab-C Risk research questions are:
1. What are the levels of SARS-CoV-2 vaccine-induced and natural immunity among VIPs compared with other groups?
2. How does persistence of SARS-CoV-2 antibodies among VIPs compare with other groups?
3. Can we identify age-specific predictors of maintained and declining SARS-CoV-2 antibodies among VIPs compared with others?
After each Phase, Ab-C publishes for a professional audience in high-impact journals, and for the public in a variety of forms, including Ab-C newsletters and interviews with the Canadian press. We plan to add video releases to be widely distributed to planners and others working with VIPs.
The Ab-C team, from six Canadian research institutions and the Angus Reid Institute, combines experience in large-scale population epidemiology, demography and biostatistics, laboratory science, clinical infectious disease, Indigenous health, health economics and priority setting, health equity, IT, communications, and knowledge translation.
Department
Program
Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
459214
Name
Jha Prabhat
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021)
Projecttitle
Ab-C Risk: Action to Beat Coronavirus Sub-study on Population Immunity in High-Risk Groups in Canada
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$499,302
Cihrequipment2
$0
Programname2
Op. Gr: Emer. COVID Res. Gaps/Prior- Dif. Impacts on Hist. Excl/Underserved Pops
Keyworddelim
Determinants Of Risk; Epidemiology; National Antibody Study; Risk Among Vunerable Canadians
Abstract
We have been studying the impact of SARS-CoV-2 infection and vaccination on immunity among a representative sample of about 20,000 Canadian adults, in the Action to Beat Coronavirus in Canada (Ab-C) study, since early in the pandemic. Ab-C Risk will recruit an additional 1,000 Canadians belonging to higher risk demographic and ethnic groups. The Ab-C cohort was recruited in collaboration with the Angus Reid Institute, which will continue to lead in surveying participants periodically about COVID-related experiences, including infection, clinical signs and symptoms, exposures, PCR testing for the virus (including variants of concern), and vaccination. Ab-C relies on participants to self-collect finger prick blood samples on special paper, and send them to Unity Health for analysis for SARS-CoV-2 antibodies. Three rounds of surveys and blood samples have been completed. A fourth and fifth round, planned into 2022, will include the new Ab-C Risk cohort.
The main Ab-C Risk research questions are:
1. What are the levels of SARS-CoV-2 vaccine-induced and natural immunity among VIPs compared with other groups?
2. How does persistence of SARS-CoV-2 antibodies among VIPs compare with other groups?
3. Can we identify age-specific predictors of maintained and declining SARS-CoV-2 antibodies among VIPs compared with others?
After each Phase, Ab-C publishes for a professional audience in high-impact journals, and for the public in a variety of forms, including Ab-C newsletters and interviews with the Canadian press. We plan to add video releases to be widely distributed to planners and others working with VIPs.
The Ab-C team, from six Canadian research institutions and the Angus Reid Institute, combines experience in large-scale population epidemiology, demography and biostatistics, laboratory science, clinical infectious disease, Indigenous health, health economics and priority setting, health equity, IT, communications, and knowledge translation.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jha, Prabhat
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $499,302~ $0~